News

Endpoints News1h
Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’
Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its ...
Endpoints News3h
AI-fo­cused biotech in­sitro cuts 22% of staff, cit­ing 'tu­mul­tuous mar­ket'
The AI-fo­cused biotech in­sitro has laid off 22% of its work­force, the com­pa­ny said in a Thurs­day state­ment. Found­ed ...
Endpoints News3h
As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions
AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...
Endpoints News4h
FDA grants Ve­rastem first ap­proval for rare ovar­i­an can­cer treat­ment
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...
Endpoints News3h
GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es
The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...
Endpoints News6h
Blood can­cer biotech Vor Bio ends clin­i­cal work, lays off 95% of staff
Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...
Endpoints News9h
HAYA Ther­a­peu­tics gets $65M for 'dark genome' work fol­low­ing last year's Lil­ly pact
After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...